A comprehensive view of Oral Medicines/Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bristol Myers Squibb reports mRNA vaccines more effective at developing COVID-19 antibodies in multiple sclerosis patients treated with oral Zeposia ozanimod than non-mRNA vaccines; observation may help in assisting physicians seeking to optimize care

Pfizer, Roivant Sciences announce Priovant Therapeutics JV; Priovant focused on developing autoimmune disease therapies including oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1to treat multiple severe autoimmune diseases

FDA approves Cybin’s New Drug Application for clinical trial evaluating oral CYB003 deuterated psilocybin analog to treat major depressive disorder; drug is first novel psilocybin analog to start clinical development, with Phase1/2a trial starting soon

Sorrento subsidiary Scilex Holding gets exclusive US rights to oral liquid gout drug Gloperba colchicine from Romeg Therapeutics; 8.7 million people in US affected by gout, with US market estimated to reach US$8.3B by 2025

Raymond James: Perrigo's acquisition of HRA Pharma may be overlooked by investors, as HRA is expected to file application for OTC birth control pill by end-2022; in light of Roe v. Wade ruling, potential annual sales of HRA pill could hit US$100M-US$200M

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count